Showing posts with label Integra LifeSciences. Show all posts
Showing posts with label Integra LifeSciences. Show all posts

Saturday, August 14, 2021

Integra LifeSciences Seeing Good Core Growth, But Inner Turbulence Is A Concern

 

It’s always worth remembering that you can like a company without liking the stock (the reverse is less often true, at least for me), and that’s certainly the case for me with Integra LifeSciences (IART) (“Integra”). I believe Integra management has done a lot of heavy lifting over the last decade or so to craft a more focused, faster-growing, and much more profitable company with a focus on niche-like markets where incoming competition is not as much of a risk as it is for other med-techs.

That said, I don’t like how the integration of ACell is going so far, and the CEO transition creates some execution risk. I also still don’t like the valuation. Integra has lagged the S&P 500 (by around 6%) and the broader medical device space (by close to 10%) since my last write-up, and I still believe that Integra is priced for double-digit top-line growth that it’s not going to get.


Read the full article here: 

Integra LifeSciences Seeing Good Core Growth, But Inner Turbulence Is A Concern

Saturday, April 10, 2021

Integra LifeSciences Shifts Toward A Better Growth/Margin Mix And Looks To Procedure Normalization

 

Integra LifeSciences (IART) has enjoyed a good run since the fall of 2020, rising more than 40% and handily beating the broader med-tech space. It seems as though investors have really liked the company’s decision to exit orthopedics and reallocate capital toward regenerative medicine, and that makes sense as it should drive better top-line growth, margins, and FCF generation.

While I saw some value in the shares back in September, the run since then has moved them to overvalued territory relative to the likely growth and margins. I don’t discount the possibility of outperformance, as Integra has shown good internal product development capabilities, but today’s valuation requires a level of growth (low double-digits) that I think is unlikely to develop.

 

Read more here: 

Integra LifeSciences Shifts Toward A Better Growth/Margin Mix And Looks To Procedure Normalization

Wednesday, September 30, 2020

Integra LifeSciences Bails Out Of A Once-Promising Growth Opportunity

Replacement joints and complementary products for the extremities make up one of the best growth markets within orthopedics, but it's not an easy market in which to sustain success - small, innovative startups are disrupting the market (including hiring away reps), while more established players like Stryker (SYK) and Wright Medical (WMGI) look to press their advantages in product development and spread of products available. It was always going to be challenging for Integra LifeSciences (IART) to become a leader here, but the company really couldn't build on its deals and has finally thrown in the towel.

Such was the performance of the extremities business that this could be addition by subtraction for Integra. At a minimum, the $200M net cash inflow reduces debt and puts management a little closer to being able to resume its growth-by-M&A strategy. All told, Integra is a tough call - the company's neuro and wound care businesses aren't bad, and the shares look a little undervalued, but this isn't a particularly fast-growing company and small/mid-cap med-techs that aren't double-digit revenue growth stories can be left behind at times.

 

Follow this link to the full article: 

Integra LifeSciences Bails Out Of A Once-Promising Growth Opportunity

Sunday, November 5, 2017

Execution Risk Back On The Table At Wright Medical

Orthopedic extremity specialist Wright Medical (WMGI) continues to be a frustrating "two steps forward, almost two steps backward" story, as fiscal third quarter results came in below expectations, and management lowered guidance on ongoing execution issues in the lower extremity business. Although the strength of the shoulder business is a meaningful positive, and the lower extremity business is hardly beyond repair, the company's inability to drive consistent execution relative to its own targets remains frustrating and an impediment to the stock.

I've previously said that Wright Medical is a stock to consider buying in the mid-$20s and selling in the mid-$30s, and I believe that remains the case. While the latest reset to expectations is disappointing, Wright Medical still has the potential to grow revenue at a high single-digit long-term rate and drive FCF margins into the 20%s. "Potential" is one of the dangerous words in investing, though, so investors have to at least consider the risk that Wright Medical's ongoing execution issues remain in place, and/or that rivals like Stryker (SYK) steal the company's thunder in the still-fast-growing extremities market.

Continue here:
Execution Risk Back On The Table At Wright Medical